Cargando…

Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report

Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomati...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Palma, Martina, Gentilini, Elio, Masucci, Chiara, Micozzi, Alessandra, Turriziani, Ombretta, Mulè, Antonino, Foà, Robin, Martelli, Maurizio, D’Ettorre, Gabriella, Capria, Saveria, Chiaretti, Sabina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084234/
https://www.ncbi.nlm.nih.gov/pubmed/35615334
http://dx.doi.org/10.4084/MJHID.2022.043
_version_ 1784703567258451968
author Di Palma, Martina
Gentilini, Elio
Masucci, Chiara
Micozzi, Alessandra
Turriziani, Ombretta
Mulè, Antonino
Foà, Robin
Martelli, Maurizio
D’Ettorre, Gabriella
Capria, Saveria
Chiaretti, Sabina
author_facet Di Palma, Martina
Gentilini, Elio
Masucci, Chiara
Micozzi, Alessandra
Turriziani, Ombretta
Mulè, Antonino
Foà, Robin
Martelli, Maurizio
D’Ettorre, Gabriella
Capria, Saveria
Chiaretti, Sabina
author_sort Di Palma, Martina
collection PubMed
description Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft.
format Online
Article
Text
id pubmed-9084234
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Università Cattolica del Sacro Cuore
record_format MEDLINE/PubMed
spelling pubmed-90842342022-05-24 Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report Di Palma, Martina Gentilini, Elio Masucci, Chiara Micozzi, Alessandra Turriziani, Ombretta Mulè, Antonino Foà, Robin Martelli, Maurizio D’Ettorre, Gabriella Capria, Saveria Chiaretti, Sabina Mediterr J Hematol Infect Dis Case Report Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft. Università Cattolica del Sacro Cuore 2022-05-01 /pmc/articles/PMC9084234/ /pubmed/35615334 http://dx.doi.org/10.4084/MJHID.2022.043 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Di Palma, Martina
Gentilini, Elio
Masucci, Chiara
Micozzi, Alessandra
Turriziani, Ombretta
Mulè, Antonino
Foà, Robin
Martelli, Maurizio
D’Ettorre, Gabriella
Capria, Saveria
Chiaretti, Sabina
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
title Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
title_full Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
title_fullStr Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
title_full_unstemmed Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
title_short Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report
title_sort management of relapsed/refractory all with inotuzumab during covid-19. a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9084234/
https://www.ncbi.nlm.nih.gov/pubmed/35615334
http://dx.doi.org/10.4084/MJHID.2022.043
work_keys_str_mv AT dipalmamartina managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT gentilinielio managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT masuccichiara managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT micozzialessandra managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT turrizianiombretta managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT muleantonino managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT foarobin managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT martellimaurizio managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT dettorregabriella managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT capriasaveria managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport
AT chiarettisabina managementofrelapsedrefractoryallwithinotuzumabduringcovid19acasereport